Statistics
Total Visits
| Views | |
|---|---|
| Clinical experience with the integrase inhibitors Dolutegravir and Elvitegravir in HIV-infected patients: efficacy, safety and tolerance | 216 |
Total Visits Per Month
| June 2023 | July 2023 | August 2023 | September 2023 | October 2023 | November 2023 | December 2023 | January 2024 | February 2024 | March 2024 | April 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical experience with the integrase inhibitors Dolutegravir and Elvitegravir in HIV-infected patients: efficacy, safety and tolerance | 0 | 0 | 0 | 0 | 0 | 3 | 11 | 7 | 0 | 2 | 1 |
File Visits
| Views | |
|---|---|
| Cid_Clinical.pdf | 263 |
Top country views
| Views | |
|---|---|
| United States | 125 |
| Spain | 21 |
| Germany | 20 |
| Ireland | 6 |
| Sweden | 5 |
| Ukraine | 5 |
| France | 4 |
| Taiwan | 4 |
| Vietnam | 3 |
| South Korea | 2 |
Top cities views
| Views | |
|---|---|
| Ashburn | 44 |
| Fairfield | 29 |
| A Coruña | 15 |
| Cambridge | 9 |
| Dublin | 5 |
| Jacksonville | 5 |
| Louisville | 5 |
| Falls Church | 4 |
| Seattle | 4 |
| Taipei | 4 |
